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disease-affected tissues and co-labeled TDP-43-positive 
inclusions in ALS spinal cord sections, confirming the 
physiological relevance of this species. These results show 
that the 35-kDa low molecular weight species in ALS-
FTLD can be generated from an abnormal splicing event 
and use of a downstream initiation codon and may represent 
a mechanism by which TDP-43 elicits its pathogenicity.
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Introduction
TAR DNA-binding protein of 43 kDa (TDP-43) is a 
nuclear DNA/RNA binding protein that has numerous 
functions in regulating RNA metabolism, including tran-
scription, alternative splicing, miRNA processing and 
mRNA stabilization [3]. TDP-43 proteinopathy is charac-
terized by the formation of neuronal cytoplasmic inclusions 
containing TDP-43, and this pathology is common to the 
majority of amyotrophic lateral sclerosis (ALS) as well as 
frontotemporal lobar degeneration (FTLD) cases [1, 16]. 
Biochemically, pathological TDP-43 comprises the normal 
full-length protein; an abnormally phosphorylated form 
that runs at 45 kDa; and lower molecular weight species 
of 25–35 kDa that correspond to N-terminally truncated 
forms of TDP-43. Expression of lower molecular weight 
species in cell culture recapitulates features of disease, 
including formation of cytoplasmic aggregates and recruit-
ment of full-length TDP-43 from the nucleus [9, 24, 26, 
29]. For C-terminal species of ~35 kDa, these effects led 
to decreased cell viability, impaired neurite outgrowth in 
Abstract The presence of lower molecular weight spe-
cies comprising the C-terminal region of TAR DNA-
binding protein 43 (TDP-43) is a characteristic of TDP-43 
proteinopathy in amyotrophic lateral sclerosis (ALS) and 
frontotemporal lobar degeneration (FTLD). Here, we have 
identified a novel splice variant of TDP-43 that is upregu-
lated in ALS and generates a 35-kDa N-terminally trun-
cated species through use of an alternate translation ini-
tiation codon (ATGMet85), denoted here as Met85-TDP-35. 
Met85-TDP-35 expressed ectopically in human neuroblas-
toma cells exhibited reduced solubility, cytoplasmic dis-
tribution, and aggregation. Furthermore, Met85-TDP-35 
sequestered full-length TDP-43 from the nucleus to form 
cytoplasmic aggregates. Expression of Met85-TDP-35 in 
primary motor neurons resulted in the formation of Met85-
TDP-35-positive cytoplasmic aggregates and motor neuron 
death. A neo-epitope antibody specific for Met85-TDP-35 
labeled the 35-kDa lower molecular weight species on 
immunoblots of urea-soluble extracts from ALS-FTLD 
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neuronal cell lines, and a loss of TDP-43 splicing activity 
[9, 24, 26, 29]. These results suggest that C-terminal spe-
cies of TDP-43 can drive pathogenesis and as such under-
standing their etiology is important for therapy develop-
ment. In this regard, the 35-kDa species described above 
were generated from different starting amino acids. Prior 
studies have shown that species of 35 and 25 kDa can be 
generated by caspase-3 cleavage at DETD89 and DVMD219, 
respectively, a phenomenon that could be triggered upon 
suppression of progranulin expression in cell culture [31]. 
Similarly, another study found that induction of apoptosis 
in cultured cells with staurosporine also led to the activa-
tion of caspase-3 and the subsequent generation of 25-kDa 
and 35-kDa TDP-43 fragments [11]. However, species of 
35 and 25 kDa are also found in cells lacking caspase-3 
[17]. As such, although the TDP-43 caspase-3 cleavage 
product runs at the same molecular weight as the 35-kDa 
C-terminal species observed in disease tissues on SDS–
polyacrylamide gel electrophoresis, one cannot infer with 
absolute certainty that the 35-kDa species in disease tis-
sues is indeed derived from caspase-3 cleavage. Therefore, 
given the role of TDP-43 in splicing of other genes [4, 6, 7, 
14] and the fact that it is alternatively spliced itself [25], we 
explored alternative splicing and/or translation as a poten-
tial mechanism for generating pathological TDP-43 C-ter-
minal species in ALS. To this end, we have identified an 
alternatively spliced variant of TDP-43 that is upregulated 
in ALS and has 91 bp spliced out in exon 2, generating a 
protein species of 35 kDa through use of a downstream 
start codon, ATGMet85, denoted here as Met85-TDP-35. Use 
of ATGMet85 as a TDP-43 start codon has previously been 
shown in cell culture studies, however, the physiological 
relevance of this was unknown [17]. Here, using a neo-
epitope antibody specifically recognizing Met85-TDP-35, 
we have shown that the pathologically associated TDP-43 
species of 35 kDa in ALS-FTLD can be generated through 
use of ATGMet85. The Met85-TDP-35 neo-epitope anti-
body not only labeled the 35-kDa species on immunoblots 
of disease tissues, but also co-labeled TDP-43-positive 
inclusions in ALS spinal cord tissue, showing that Met85-
TDP-35 is fully integrated within the pathology associated 
with the disease. These findings indicate that pathological 
variants of TDP-43 can be generated through a combina-
tion of alternative splicing and translation, mechanisms that 
could be targeted therapeutically.
Materials and methods
ALS and control cases
Spinal cord tissues were collected from eleven sALS cases, 
four with C9orf72 repeat expansions, and one fALS case 
also carrying a C9orf72 repeat expansion [27]; and one 
case each of Alzheimer’s disease, corticobasal degen-
eration, multisystem atrophy and Huntington’s disease 
(Table 1). Prefrontal cortex tissues were collected from six 
ALS cases with pathologically confirmed FTLD, and six 
neurologically normal control cases (Table 1). ALS cases 
were diagnosed using the Revised El Escorial Criteria 
(Brooks 2000), and patient consents were obtained from 
the legal representatives in accordance with the Ethical 
Review Boards of Sunnybrook Health Sciences Centre and 
University of Toronto (Toronto, Canada).
RT‑PCR and cloning of TDP‑43 and its splice variant
Fifty milligrams of gray matter was dissected from the 
anterior horn of postmortem lumbar spinal cord from 
twelve ALS and four control cases, from which total RNA 
Table 1  ALS and control cases used in this study
sALS sporadic ALS, fALS familial ALS, FTLD frontotemporal lobar 
degeneration, C9orf72 chromosome 9 open reading frame 72, N/A not 
applicable, AD Alzheimer’s disease, CBD corticobasal degeneration, 
MSA multiple system atrophy, HD Huntington’s disease, N.N. neuro-
logically normal
Cases Sex Age (years) Diagnosis Gene mutation
ALS cases
 A1 F 49 sALS-FTLD C9orf72
 A2 F 46 sALS N/A
 A3 F 73 sALS N/A
 A4 M 70 sALS C9orf72
 A5 F 58 sALS-FTLD C9orf72
 A6 F 59 sALS N/A
 A7 M 52 sALS N/A
 A8 F 65 sALS N/A
 A9 M 58 fALS-FTLD C9orf72
 A10 F 60 sALS N/A
 A11 M 64 sALS-FTLD C9orf72
 A12 F 57 sALS N/A
 A13 F 83 sALS-FTLD N/A
 A14 F 71 sALS-FTLD N/A
Control cases
 C1 F 91 AD N/A
 C2 M 77 CBD N/A
 C3 M 69 MSA N/A
 C4 F 78 HD N/A
 C5 M 76 N.N. N/A
 C6 M 74 N.N. N/A
 C7 M 89 N.N. N/A
 C8 F 48 N.N. N/A
 C9 M 54 N.N. N/A
 C10 F 82 N.N. N/A
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was extracted using TRIzol Reagent (Life Technologies) 
according to the manufacturer’s protocol and treated with 
DNase to minimize DNA contamination. The RNA tran-
scripts were first normalized with β-actin primers (Life 
Technologies) after synthesizing complementary DNA 
(cDNA) from 1 μg of total RNA using random hexam-
ers and the SuperScript III First-strand Synthesis System 
for RT-PCR (Life Technologies) following manufacturer’s 
protocol. PCR was performed with 2 μl of template cDNA 
mixed with 18 μl of reaction mix containing 10 μl of 2× 
Master Mix (Life Technologies), 6 μl water, 1 μl of 10 μM 
forward primer (5′-ATG TCT GAA TAT ATT CGG GTA 
AC-3′) and 1 μl of 10 μM reverse primer (5′-GTC CAT 
CTA TCA TAT GTC GCT GTG-3′). Amplification of TDP-
43 and its splice variant was performed in a 9800 Fast Ther-
mal Cycler (Life Technologies) with an initial denaturation 
at 95 °C for 10 s, followed by 35 cycles of denaturation at 
95 °C for 0 s and annealing at 66 °C for 15 s. The ampli-
fied products were visualized on a 1.5 % (w/v) agarose/eth-
idium bromide gels and subjected to sequence verification.
For cloning of full-length TDP-43 and its splice vari-
ant, 1 μg total RNA isolated from ALS spinal cords was 
reverse transcribed with an adapter-tagged oligo dT 
primer (oligo(dT)17-GGC CAC GCG TCG ACT AGT 
AC) into cDNA, which was purified with a Rapid Ampli-
fication of cDNA Ends (RACE) Purification System 
(Life Technologies). Poly-(dC) sequences were added 
to the N-terminus of 10 μl cDNA using a TdT-tailing 
reaction (6.5 μl DEPC-treated water, 5 μl of 5× tail-
ing buffer, 2.5 μl of 2 mM dCTP, and 1 μl TdT) accord-
ing to manufacturer’s protocol (Life Technologies). PCR 
was performed with 5 μl of tailed cDNA with 45 μl PCR 
reaction mix containing 1× PfuUltra buffer, 200 μM 
dNTP, 0.2 μM 5′RACE abridged anchor primer (5′-
GGC CAC GCG TCG ACT AGT ACG GGI IGG GII GGG 
IIG-3′), 0.2 μM adapter primer (5′-GGC CAC GCG TCG 
ACT AGT AC-3′), and 1.25 U PfuUltra DNA polymerase 
(Agilent Technologies). Amplification of PCR products was 
performed with an initial denaturation at 95 °C for 45 s, fol-
lowed by 25 cycles of denaturation at 95 °C for 45 s, 55 °C 
for 45 s, and 68 °C for 90 s in GeneAmp PCR System 9700 
(Life Technologies). The amplified products were puri-
fied with Qiagen PCR Purification Kit (Qiagen) and were 
subjected to a second round of amplification with a 5′UTR 
forward primer with a NotI restriction site (5′-ataagaatgcg-
gccgcGTC CGT CGC TGC TTC GGT G-3′) and a 3′UTR 
reverse primer with a BamHI restriction site (5′-atacgcg-
gatccGCC TGT GAT GCG TGA TGA CG-3′). The PCR 
conditions were the same as the first round except with 30 
cycles. The amplified products were visualized on a 1.0 % 
(w/v) agarose/ethidium bromide gel, purified with the Min-
iElute Gel Extraction Kit (Qiagen), and then subcloned 
into the NotI/BamHI restriction sites of the mammalian 
expression vector pcDNA3.1(−). The Met85-TDP-35 con-
struct, starting at the 3rd ATG (Met85) of full-length TDP-
43, was generated by PCR and cloned into pcDNA3.1(−) 
expression vector using a forward primer containing a 
BamHI restriction site (5′-gcggatccaccATG GAT GAG 
ACA GAT GCT TC-3′) and a reverse primer containing 
a KpnI restriction site (5′-cacggtacCTA CAT TCC CCA 
GCC AGA AGA CTT AG-3′). For visualization of the 
subcellular localization of full-length TDP-43 and Met85-
TDP-35, these two sequences were cloned into pEGFP-C2 
and pmRFP-C2 vectors, for N-terminal tagging with EGFP 
and RFP, respectively. Sequence analysis was performed on 
all constructs to ensure correct sequences.
Silver staining
PCR amplified products were resolved on 10 % native 
PAGE (polyacrylamide gel electrophoresis) gels followed 
by fixation in 10 % ethanol, 0.05 % acetic acid for 30 min. 
Gels were then stained with a 10 mM silver nitrate solu-
tion for 30 min, developed in a 350 mM sodium hydrox-
ide, 0.3 % formaldehyde solution, and the reaction stopped 
using 5 % acetic acid. Gel images were captured and band 
intensities quantified using Image J software with values 
expressed as mean ± standard error of the mean (SEM).
Cell culture and microinjection of primary motor 
neurons
The human neuroblastoma cell line SH-SY5Y was main-
tained in DMEM/F12 medium (Life Technologies) sup-
plemented with 10 % fetal bovine serum (FBS). Transfec-
tion was performed with the corresponding plasmid DNAs 
using Lipofectamine 2000 (Life Technologies) following 
manufacturer’s protocol. Generation of primary motor 
neuron cultures was as described previously [21, 28], and 
plasmids containing EGFP-tagged full-length TDP-43 
and EGFP-tagged Met85-TDP-35 in pEGFP-C2 vector 
were microinjected at 200 ng/μl into motor neuron nuclei 
along with 20 μg/μl of the fluorescent marker Dextran 
FITC (Life Technologies). Cell viability was determined 
daily by counting the number of FITC-positive motor 
neurons, which was normalized to the number of FITC-
positive motor neurons on day 1 after microinjection. All 
experiments were performed in triplicate and values were 
expressed as mean ± SEM.
Immunocytochemistry of cultured cells
To visualize EGFP-tagged construct expression, cultured 
cells grown on glass coverslips were fixed with 3.7 % (w/v) 
paraformaldehyde in phosphate-buffered saline (PBS) for 
20 min at room temperature (RT) followed by 3 × 5 min 
52 Acta Neuropathol (2015) 130:49–61
1 3
PBS washes then counterstained with 4′,6-diamidino-
2-phenylindole (DAPI) nucleic acid stain for 1 min (Life 
Technologies). Immunofluorescence was visualized using 
a Leica DMI6000 microscope and images captured using 
Volocity software (PerkinElmer).
Protein extraction and Western blotting
SH-SY5Y cells grown on 35 mm2 dishes (Thermo Sci-
entific) were harvested in 1 ml PBS containing protease 
inhibitors at 4 °C, and the cell suspensions were centri-
fuged at 500×g for 5 min at 4 °C. The resulting pellets 
were homogenized in 1 ml low salt buffer [50 mM Tris, 
pH 7.5, 150 mM NaCl, 5 mM ethylenediaminetetraacetic 
acid (EDTA)] containing protease inhibitors (Sigma-
Aldrich) and then centrifuged at 16,100×g for 20 min at 
4 °C. Supernatants were saved as the low salt fraction, 
and pellets were homogenized in a high salt Triton X-100 
buffer (50 mM Tris, pH 7.5, 750 mM NaCl, 5 mM EDTA, 
1 % Triton X-100, and protease inhibitors), followed by 
centrifugation at 16,100×g for 20 min at 4 °C. Superna-
tants were saved as the high salt Triton X-100 fraction, 
and the remaining pellets were solubilized in urea buffer 
(7 M urea, 2 M thiourea, 4 % 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS), 30 mM 
Tris–HCl, pH 8.5) and saved as the urea fraction.
For human tissues, gray matter from ALS and con-
trol lumbar spinal cord was dissected and weighed, then 
homogenized at 200 mg/ml using the same biochemi-
cal fractionation procedure as for cultured cells but with 
one exception: after extraction in high salt Triton X-100 
buffer, the resulting pellets were homogenized in a high 
salt sucrose buffer (50 mM Tris, pH 7.5, 750 mM NaCl, 
5 mM EDTA, 30 % sucrose, and protease inhibitors), fol-
lowed by centrifugation at 16,100×g for 30 min at 4 °C 
to float and remove myelin. For immunoblotting, sodium 
dodecyl sulfate (SDS) sample buffer (10 mM Tris–HCl, 
pH 6.8, 1 mM EDTA, 40 mM DTT, 1 % SDS, and 10 % 
sucrose) was added to 50 μg of each sample fraction, 
which was heated at 95 °C for 5 min with the exception 
of the urea fraction to avoid carbamoylation of proteins. 
Equivalent amounts of protein samples were loaded onto 
10 % SDS-PAGE gels and transferred to polyvinyldiflour-
ide (PVDF) membranes, which were blocked in 5 % skim 
milk dissolved in Tris-buffered saline (TBS) contain-
ing 0.2 % Tween-20 for 1 h at RT, followed by overnight 
incubation at 4 °C with a polyclonal TDP-43 antibody 
(1:1000, Proteintech), a polyclonal N-terminal TDP-43 
antibody (1:1000, Aviva Systems Biology), or a poly-
clonal C-terminal TDP-43 antibody (1:1000, generated 
in-house using a synthetic peptide, FGSSMDSKSSGWG, 
linked to keyhole limpet hemocyanin as the antigen). 
Bound antibody was visualized with an ECL Detection 
System (PerkinElmer) using HRP-conjugated secondary 
antibodies.
To extract insoluble proteins from the prefrontal cor-
tex, six ALS cases with pathologically confirmed FTLD-
TDP-43, and six neurological normal controls of a similar 
age group were included. Tissue was dissected from Brod-
mann’s area 10, weighed, and homogenized at 250 mg/ml 
in low salt buffer (10 mM Tris–HCl, pH 7.5, 5 mM EDTA, 
1 mM DTT, 10 % sucrose, and protease inhibitors) with a 
glass Dounce homogenizer (Sigma-Aldrich). Homogen-
ate was centrifuged at 25,000×g for 30 min at 4 °C, and 
the resulting supernatant was saved as the low salt frac-
tion. Pellet was homogenized at 250 mg/ml (starting tis-
sue weight) in high salt buffer (low salt buffer + 500 mM 
NaCl, 1 % Triton X-100, and protease inhibitors) and cen-
trifuged at 180,000×g for 30 min at 4 °C, and the resulting 
supernatant was saved as the high salt fraction. Pellet was 
homogenized in 250 mg/ml (starting tissue weight) myelin 
flotation buffer (10 mM Tris–HCl, pH 7.5, 500 mM NaCl, 
5 mM EDTA, 1 mM DTT, 40 % sucrose, 1 % Triton X-100, 
and protease inhibitors) and centrifuged at 180,000×g 
for 30 min at 4 °C, and the floating myelin removed. The 
resulting supernatant was saved as the myelin flotation frac-
tion. Pellet was homogenized in 50 mg/ml (starting tissue 
weight) sarkosyl buffer (low salt buffer + 500 mM NaCl, 
1 % N-lauroyl-sarcosine, and protease inhibitors) and incu-
bated with agitation at 22 °C for 30 min, followed by cen-
trifugation at 180,000×g for 30 min at 22 °C. The resulting 
supernatant was saved as the sarkosyl fraction. Pellet was 
sonicated with the Ultrasonic Cell Disrupter (Misonix) in 
1 g/ml (starting tissue weight) urea buffer (30 mM Tris–
HCl, pH 8.5, 7 M urea, 2 M thiourea, 4 % CHAPS) and 
saved as the urea fraction. All fractions were resuspended 
with SDS sample buffer and all samples except for the urea 
fraction were heated at 95 °C for 5 min prior to SDS-PAGE 
and immunoblot analyses.
Generation of neo‑epitope antibodies
Rabbit polyclonal antibodies specifically recognizing 
Met85-TDP-35 or caspase-3-cleaved TDP-35 (C3-TDP-35) 
were generated using synthetic peptides corresponding to 
the neo-epitopes generated by alternative translation ini-
tiation at ATGMet85 (M85DETDASSA) or caspase-3 cleav-
age at DETD89 (A90SSAVKVKR), respectively, linked to 
keyhole limpet hemocyanin (ProSci Inc.). Both antibod-
ies were diluted 1:1000 for immunoblotting and 1:500 for 
immunohistochemistry.
Generation of recombinant TDP‑43 protein
Full-length TDP-43 was expressed as a fusion protein 
with His-tagged Venus YFP at the N-terminus joined by 
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a TEV-cleavable linker. The construct was cloned into 
the pET-30 vector (EMD Millipore) and expressed in E. 
coli BL21-AI cells (Life Technologies). Bacterial culture 
was lysed by sonication on ice with lysis buffer (40 mM 
HEPES–KOH, pH 7.4, 500 mM KCl, 20 mM MgCl2, 10 % 
glycerol, 20 mM imidazole, 2 mM β-mercaptoethanol) 
containing protease inhibitors (Roche Applied Science). 
Lysate was centrifuged at 15,000 RPM in a Sorvall SS-34 
rotor for 30 min at 4 °C. Prior to Ni–NTA agarose bead 
column (Qiagen) purification of the lysate supernatant, 
the column was washed with 5 column volumes of 40 mM 
HEPES–KOH, pH 7.4, 500 mM KCl, 20 mM MgCl2, 10 % 
glycerol, 20 mM imidazole, 2 mM β-mercaptoethanol, 
and protease inhibitors. The YFP-TDP-43 fusion protein 
was eluted from the column with 40 mM HEPES, pH 7.4, 
500 mM KCl, 20 mM MgCl2, 250 mM imidazole, 10 % 
glycerol, 2 mM β-mercaptoethanol, and protease inhibitors. 
SDS-PAGE analysis of eluent showed that the fusion pro-
tein fraction was 95 % pure.
In vitro caspase‑3 cleavage of recombinant TDP‑43
To generate caspase-3-cleaved TDP-43, 2 μg of recombi-
nant human YFP-tagged TDP-43 was incubated with 2 U of 
active human recombinant caspase-3 (EMD Millipore) in 
a reaction mix containing 100 mM NaCl, 50 mM HEPES, 
10 mM DTT, 1 mM EDTA, 10 % glycerol, and 0.1 % 
CHAPS, pH 7.4, at 37 °C for 4 h. The reaction was halted 
by adding 2× SDS sample buffer.
Immunohistochemistry of human spinal cord tissues
Formalin-fixed paraffin-embedded lumbar spinal cord 
tissues from ALS and control cases were cut into 4 μm 
serial sections and then mounted on glass slides. Tissue 
sections were rehydrated in sequential washes of xylene, 
xylene:ethanol (1:1), and decreasing concentrations of 
ethanol, followed by a final wash in PBS. Blocking of 
endogenous peroxidase activity was achieved by incubation 
with 3 % (v/v) hydrogen peroxide, and antigens retrieved 
by incubation in either 10 mM citrate buffer at pH 6.0 for 
polyclonal TDP-43 antibody (ProteinTech) or Tris–EDTA 
buffer (20 mM Tris–HCl, 0.65 mM EDTA, 0.0005 % 
Tween-20, pH 9.0, for Met85-TDP-35 antibody). Sections 
were incubated overnight at RT with polyclonal TDP-43 
antibody (1:5000, Proteintech) or Met85-TDP-35 antibody 
(1:500) diluted in antibody diluent (0.05 M Tris–HCl, pH 
7.4, 0.25 % Tween-20, 0.2 % Triton X-100, 1 % casein, 
and 0.05 % thimerosol). Bound antibody was visualized 
using the ImmPRESS Anti-rabbit Ig Peroxidase Kit (Vec-
tor Labs) for polyclonal TDP-43 antibody or with the Super 
Sensitive Polymer HRP Kit (Biogenex) for Met85-TDP-35 
antibody labeling. Color development was achieved using 
NovaRed (Vector Labs) and sections were counterstained 
with hematoxylin. Images were captured using a QImag-
ing Micropublisher 3.3 RTV digital camera attached to a 
Leica DM6000 upright microscope and Openlab Imaging 
software (PerkinElmer).
For double immunofluorescence labeling, formalin-
fixed paraffin-embedded spinal cords were cut into 6 μm 
sections and subjected to the same processing as above, 
except that the primary antibodies were rabbit polyclonal 
Met85-TDP-35 antibody (1:500) and mouse monoclo-
nal TDP-43 antibody (2E2-D3, 1:500, Novus Biologi-
cals) and the secondary antibodies were goat anti-rabbit 
Alexa Fluor 488 and goat anti-mouse Alexa Fluor 594, 
respectively. Images were captured with an ORCA ER 
Hamamatsu digital camera mounted on a Leica DMI600 
inverted microscope using Volocity Imaging software 
(PerkinElmer).
Results
Identification of a novel splice variant of TDP‑43
A search of EST sequences in Genbank (http://www.ncbi.
nlm.nih.gov/genbank/) yielded two human (accession 
numbers: BI464234 and BG435185) and fourteen mouse 
(accession numbers: AV506877, AW 106495, BU610138, 
BY740492, BY788083, CA319629, CA543520, CA879844, 
CD553499, CD766458, CN691221, CN692254, CN696163, 
and DV060848) EST sequences, which revealed the same 
91 bp splicing deletion in exon 2 of TARDBP, encoding 
TDP-43. This splice variant uses a non-canonical splic-
ing pair (UU:AG), thus skipping base pairs 106–196 within 
exon 2 (denoted here as TDP-43 r.[106_196del]). To investi-
gate the relevance of this splice variant in ALS, we selected 
twelve cases (11 sALS and one fALS with C9orf72 expan-
sions), all of which exhibited TDP-43- and ubiquitin-pos-
itive inclusions upon postmortem examination, and 4 con-
trol cases for transcript analysis. RT-PCR was performed 
using total RNA isolated from lumbar spinal cords, with a 
forward primer located in exon 2 and a reverse primer in 
exon 4 of TARDBP (Fig. 1a). A major band of 511 bp, cor-
responding to the full-length TDP-43 transcript, was present 
across all ALS and control cases. A lower band of 420 bp 
that corresponds to the alternatively spliced variant TDP-
43 r.[106_196del] was found at much higher levels in ALS 
cases compared to controls (Fig. 1b). After normalization of 
total RNA to β-actin, quantification analysis showed that the 
TDP-43 r.[106_196del] transcript was upregulated by ~4.0 
fold (p < 0.0126) in ALS (n = 12; 0.216 ± 0.031) compared 
to controls (n = 4; 0.059 ± 0.013) (Fig. 1c).
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TDP‑35 is an N‑terminally truncated protein 
with reduced solubility
Translation tool analysis (http://www.expasy.org/tools/) of 
the TDP-43 splice variant transcript showed that if it was 
transcribed from the first ATGMet1, the 91 bp deletion in 
exon 2 would cause a frame shift and generate a premature 
stop codon (TAG) 190–192 bp downstream from ATGMet1, 
thereby producing a short protein of 63 aa with a pI/MW of 
4.32/7.2 kDa. Theoretically, such mRNA transcripts con-
taining premature stop codons would be eliminated through 
nonsense-mediated mRNA decay [8], which was corrobo-
rated in our findings as we did not detect a protein product 
of this size across our studies. However, translation analy-
sis also revealed the presence of a complete open reading 
frame (ORF) situated 161 bp downstream from ATGMet1. 
The ATG initiation codon of this ORF corresponds to the 
third ATGMet85 of full-length TDP-43, with the loss of the 
second ATGMet51 through the splicing deletion (Fig. 2).
Expression of the TDP-43 r.[106_196del] cDNA in 
pcDNA3.1(−) in human neuroblastoma (SH-SY5Y) cells 
resulted in the generation of a 35-kDa protein product on 
immunoblots of cell lysates, thereby confirming the predic-
tion described above (Fig. 3). To biochemically character-
ize this 35-kDa species, SH-SY5Y cells expressing full-
length TDP-43, TDP-43 r.[106_196del], or Met85-TDP-35 
(generated by PCR) were harvested and proteins sequen-
tially extracted with buffers of increasing stringency, fol-
lowed by immunoblot analysis of all fractions (Fig. 3). 
Fig. 1  TDP-43 r.[106_196del] splice variant is upregulated in ALS. 
a TARDBP gene structure showing splicing deletion. Black boxes are 
exons. White box in exon 2 denotes the 91 bp skipped by alternative 
splicing. Arrows indicate positions of the forward and reverse primers 
for RT-PCR. b RT-PCR amplification of the TDP-43 r.[106_196del] 
splice variant using RNA isolated from ALS and control spinal 
cord. Region amplified has 511 bp in the constitutively spliced tran-
script and 420 bp in the alternatively spliced transcript. Cases A1, 
A4, A5, A9, and A11 also carry C9orf72 expansions. c Quantifica-
tion using ImageJ showed a ~4 fold upregulation of the splice vari-
ant in ALS (n = 12; 0.216 ± 0.031) compared to controls (n = 4; 
0.059 ± 0.013), p < 0.0126
Fig. 2  Sequence alignment 
of TDP-43 and the TDP-43 
r.[106_196del] splice variant. 
The 91 bp splicing deletion is 
signified by dotted lines. Pat7 
(aa 78–84, shown in bold ital-
ics) and bipartite (aa 82–98, 
boxed) nuclear localization 
sequences are indicated. Note 
that ATGMet85 immediately 
precedes the caspase-3 cleavage 
site DETD89 (underlined)
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Full-length TDP-43 distributed to all fractions, as has been 
reported previously, whereas the 35-kDa species expressed 
from TDP-43 r.[106_196] and Met85-TDP-35 was exclu-
sively partitioned to the urea-soluble fraction (Fig. 3), indi-
cating a decreased solubility compared to the full-length 
protein. Both TDP-43 r.[106_196del] and Met85-TDP-35 
were detected with an antibody to the C-terminus of TDP-
43, but not to the N-terminus, confirming the loss of the 
N-terminal domain in these proteins (Fig. 3).
TDP‑35 has disrupted nuclear localization signals 
and forms cytoplasmic aggregates in human 
neuroblastoma cells
Given that Met85-TDP-35 is translated from the third 
ATGMet85 of full-length TDP-43, there is disruption of 
two NLS sequences located within the N-terminal region 
of the full-length protein, namely, the Pat7 NLS from aa 
78–84 (PKDNKRK) and the bipartite NLS from aa 82–98 
(KRKMDETDASSAVKVKR) (Fig. 2). To examine the 
subcellular localization of full-length TDP-43 and Met85-
TDP-35, EGFP tags were added to either the N-terminus or 
the C-terminus of these two constructs to visualize ectopic 
expression in SH-SY5Y cells. EGFP-tagged full-length 
TDP-43 exhibited a nuclear distribution that colocalized 
with DAPI labeling, whereas EGFP-tagged Met85-TDP-35 
localized to the cytoplasm exhibiting three distinct pat-
terns: Type I showed that 60 % of transfected cells had a 
diffuse Met85-TDP-35 localization in both the nucleus and 
the cytoplasm; Type II showed that 25 % of transfected 
cells had diffuse Met85-TDP-35 localization accompanied 
with small cytoplasmic aggregates, and Type III showed 
Fig. 3  TDP-43 r.[106_196del] 
splice variant generates an 
N-terminally truncated protein 
of 35 kDa. SH-SY5Y cells 
expressing full-length TDP-
43, TDP-43 r.[106_196del], 
Met85-TDP-35, or mock vector 
were fractionated in buffers of 
increasing stringency: a low 
salt; b high salt-TX-100; c–e 
urea buffer. Full-length TDP-
43 was found in all fractions 
on immunoblots probed with 
polyclonal TDP-43. A lower 
molecular weight species of 
35 kDa was observed only in 
urea-soluble fractions of lysates 
from cells expressing TDP-
43 r.[106_196del] or Met85-
TDP-35 (c) and was detected 
using antibody to the C-termi-
nus of TDP-43 (d) but not to the 
N-terminus (e). f Comparative 
structures of TDP-43 and Met85-
TDP-35
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that 15 % of transfected cells had large Met85-TDP-35 
aggregates in the cytoplasm but no labeling in the nucleus 
(Online Resource 1). These results recapitulate previous 
studies [9, 29]. The Met85-TDP-35-positive cytoplasmic 
aggregates did not label with antibodies to ubiquitin or 
phosphorylated TDP-43 (409/410) (not shown). Moreo-
ver, as observed previously for other TDP-43 species with 
disrupted NLS [9, 29], Met85-TDP-35 recruited full-length 
TDP-43 from the nucleus into the cytoplasm, where it 
formed aggregates (Online Resource 1).
Met85‑TDP‑35 forms cytoplasmic aggregates and is 
toxic to primary motor neurons
To examine the effect of expressing Met85-TDP-35 in an 
ALS-relevant cell type, plasmids encoding N-terminal 
EGFP-tagged full-length TDP-43, N-terminal EGFP-
tagged Met85-TDP-35, or empty vector were expressed in 
primary motor neurons using intranuclear microinjection. 
Full-length TDP-43 localized exclusively to the nucleus, 
whereas Met85-TDP-35 was found in the cytoplasm of pri-
mary motor neurons, where it appeared as punctate aggre-
gates similar to those observed in transfected SH-SY5Y 
cells (Fig. 4a). Cell viability assays conducted over a 
period of 1 week showed that expression of Met85-TDP-35 
induced motor neuron death with a 50 % loss at day 5 post-
microinjection, compared to full-length TDP-43, which 
exhibited no toxicity with a similar cell viability curve as 
neurons expressing the empty vector (Fig. 4b).
Met85‑TDP‑35 expression in ALS
As our studies in cultured cell lines and primary motor 
neurons indicated that Met85-TDP-35 formed cytoplasmic 
aggregates, recapitulating a characteristic feature of TDP-
43 proteinopathy, we proceeded to assess the pathologi-
cal relevance of Met85-TDP-35 in ALS disease tissues. To 
study the presence of Met85-TDP-35, gray matter from the 
anterior horn of four sALS and four control lumbar spinal 
cords were sequentially extracted with buffers of increasing 
stringency to isolate insoluble proteins (Online Resource 
2). Equivalent amounts of low salt, high salt Triton X-100 
and urea fractions were immunoblotted with polyclonal 
TDP-43 antibody (Proteintech), which immunolabeled full-
length TDP-43 in all fractions but also a distinct 35-kDa 
species that was only present in the urea fraction of ALS 
samples (Online Resource 2). This 35-kDa species was 
immunolabeled with C-terminal TDP-43 antibody but not 
with N-terminal TDP-43 antibody (Online Resource 2), 
confirming that this is a lower molecular weight C-terminal 
species frequently observed in disease tissues. The 25-kDa 
species could be observed at much longer exposures of the 
immunoblots (Online Resource 2). To determine whether 
this 35-kDa C-terminal species was generated through 
translation from Met85 or from caspase-3 cleavage at 
DETD89, we generated neo-epitope antibodies specific for 
the extreme N-terminal sequences of these two proteins, 
termed Met85-TDP-35 antibody or C3-TDP-35 antibody, 
respectively (Fig. 5a). Specificity of the antibodies for their 
respective protein isoforms was confirmed by immunoblot-
ting using cell lysates expressing TDP-43 r.[106_196del] 
or full-length recombinant TDP-43 cleaved with caspase-3 
in vitro (Fig. 5b–d). Immunoblotting of the urea fractions 
of ALS and control spinal cords tissues with polyclonal 
TDP-43 antibody revealed a distinct 35-kDa species pre-
sent only in ALS samples in addition to the full-length 
TDP-43 (Fig. 5e). This 35-kDa species was immunola-
beled by the neo-epitope Met85-TDP-35 antibody (Fig. 5f) 
but not by C3-TDP-35 antibody (Fig. 5g). Given that the 
discovery of TDP-43 proteinopathy linked the two previ-
ously separate diseases, ALS and FTLD, into one disease 
spectrum, we examined the presence of Met85-TDP-35 in 
ALS-FTLD brain tissue. Tissues were extracted from the 
prefrontal cortex, more specifically the most anterior region 
Fig. 4  Expression of Met85-TDP-35 causes death of primary motor 
neurons. a Expression of EGFP-tagged TDP-43 and EGFP-tagged 
Met85-TDP-35 in primary motor neurons resulted in localization of 
TDP-43 to the nucleus and Met85-TDP-35 to the cytoplasm, where 
it formed aggregates (arrow). b A viability curve showed that Met85-
TDP-35 induced motor neuron death compared to TDP-43 or empty 
vector alone. Scale bar 20 μm
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of Brodmann’s area 10, since this represents a region that 
usually exhibits extensive TDP-43 proteinopathy in FTLD 
[5]. A pathological species of 35 kDa was clearly detected 
in four of the six ALS-FTLD cases, not in controls, and 
was detected with Met85-TDP-35 antibody (Fig. 5h).
To determine whether Met85-TDP-35 is incorporated 
within pathological inclusions, immunohistochemical labe-
ling with polyclonal TDP-43 antibody and Met85-TDP-35 
antibody was performed on serial sections of ALS lumbar 
spinal cord. Met85-TDP-35 antibody co-labeled the same 
Fig. 5  Antibody to Met85-TDP-35 detects Met85-TDP-35 in ALS 
and ALS-FTLD tissues. a Synthetic peptide sequences used for gen-
eration of neo-epitope rabbit polyclonal antibodies specific to Met85-
TDP-35 (underlined in red) and C3-TDP-35 (underlined in green). 
b–d Neo-epitope antibodies were characterized using lysates of 
cells expressing TDP-43 r.[106_196del], recombinant YFP-tagged 
full-length TDP-43 (YFP-TDP-43), and recombinant YFP-tagged 
full-length TDP-43 cleaved with caspase 3 (C3-cleaved). Note that 
there is a caspase-3 cleavage site at DEND13 of full-length TDP-43, 
which cleaves the YFP tag (asterisk); and at DVMD19, generating a 
cleavage product of 25 kDa (arrowhead). e–g Urea-soluble fractions 
of spinal cord extracts from four ALS cases (A1–A4) and four con-
trols (C1–C4) were immunoblotted with polyclonal TDP-43 anti-
body (e), Met85-TDP-35 antibody (g), and C3-TDP-35 antibody (g). 
The 35-kDa TDP-43 species (arrowhead) in ALS tissue was detected 
with polyclonal TDP-43 antibody and Met85-TDP-35 antibody but 
not with C3-TDP-35 antibody. Full-length TDP-43 (arrow) was not 
detected by the Met85-TDP-35 antibody. The location of the 25-kDa 
species is shown with an asterisk. The 72-kDa band detected by the 
C3-TDP-35 antibody is non-specific (double asterisk). h Urea-soluble 
fractions of prefrontal cortex extracts from six patients with ALS-
FTLD and six controls were immunoblotted with Met85-TDP-35 
antibody. In four out of six patient samples, a 35-kDa species cor-
responding to Met85-TDP-35 was apparent and was absent from all 
control samples. An additional band of 37 kDa was also apparent in 
one patient sample, the identity of which is unknown. Cases A1, A4, 
A5, A9, and A11 also carry C9orf72 expansions
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pathological inclusions as polyclonal TDP-43 antibody 
(Fig. 6a), and this labeling could be abrogated by compe-
tition with the peptide used to generate the Met85-TDP-35 
antibody (Fig. 6b). In contrast, there was no labeling of 
TDP-43-positive inclusions with C3-TDP-35 antibody 
(Fig. 6c). Double fluorescence labeling showed labeling of 
the nucleus in normal motor neurons of control cases with 
mouse monoclonal TDP-43 antibody, and absence of labe-
ling with Met85-TDP-35 antibody, confirming that Met85-
TDP-35 neo-epitope antibody did not cross-react with 
full-length TDP-43 (Fig. 6d). In contrast, double fluores-
cence labeling of motor neurons in ALS lumbar spinal cord 
showed co-labeling of both round and skein like inclusions 
with the polyclonal TDP-43 antibody and Met85-TDP-35 
antibody, confirming that Met85-TDP-35 is incorporated 
together with full-length TDP-43 within the pathological 
inclusions characteristic of ALS (Fig. 6d).
Discussion
TDP-43 proteinopathy is the hallmark of the majority of 
ALS-FTLD cases, and biochemical characterization of 
pathological TDP-43 from disease tissues indicates that 
abnormal lower molecular weight TDP-43 species com-
prising the C-terminal region may play a role in disease 
pathogenesis [16]. Understanding the etiology of such spe-
cies is important to advancing our understanding of TDP-
43 pathogenicity. Here, we have provided evidence that 
the 35-kDa lower molecular weight species observed in 
diseases tissues can be derived from expression of an alter-
native splice variant of TDP-43. This splice variant, TDP-
43 r.[106_196del], is upregulated approximately four-fold 
in ALS spinal cord compared to controls and is generated 
using non-canonical splice sites that skip the base pairs 
106–196 in exon 2 of TARDBP, causing a frame shift and 
generating a premature termination codon 190 bp down-
stream from the first ATG. However, we have shown that a 
translation reinitiation event from the third ATGMet85 leads 
to the expression of an N-terminally truncated TDP-43 pro-
tein, denoted here as Met85-TDP-35, that has a disrupted 
NLS. Use of ATGMet85 as an alternative TDP-43 start site 
has been reported previously in cell culture studies showing 
that TDP-43 species of 35 kDa can be generated independ-
ent of caspase-3 cleavage [9, 17, 29]. Here, we have estab-
lished the physiological relevance of this isoform in ALS 
and FTLD-TDP and shown that it can be generated via an 
abnormal splicing event.
As has been reported for other N-terminally truncated 
35-kDa species of TDP-43 [9, 29], Met85-TDP-35 had 
reduced solubility, a cytoplasmic localization and formed 
aggregates when expressed in human neuroblastoma cells, 
all of which are predominant features of pathological 
TDP-43 in ALS and FTLD [1, 15]. Moreover, co-expres-
sion of Met85-TDP-35 with full-length TDP-43 resulted in 
a redistribution of full-length TDP-43 from the nucleus to 
the cytoplasm, where it was sequestered into Met85-TDP-
35-positive inclusions. These inclusions were not labeled 
with ubiquitin or TDP-43 phosphorylation-dependent anti-
bodies, supporting earlier studies showing that aggregation 
can occur in the absence of these modifications [12, 13, 22]. 
Given that TDP-43 has been shown to form homodimers 
[23], Met85-TDP-35 could potentially interact with TDP-43 
and sequester it into cytoplasmic inclusions, thereby pro-
viding a possible mechanism for a gain-of-function toxic-
ity of cytoplasmic Met85-TDP-35 and at the same time a 
loss-of-function resulting from a depletion of nuclear TDP-
43. This potential mechanism of action has been proposed 
by others and our data fully support this premise [9, 26]. 
Importantly, our findings have shown that expression of 
Met85-TDP-35 in primary motor neurons led not only to 
formation of cytoplasmic aggregates, but also to decreased 
cell viability, demonstrating that Met85-TDP-35 can induce 
death of the neuronal type affected in ALS.
Although original studies have reported lower molec-
ular weight TDP-43 species of ~25 kDa in FTLD brain 
tissues [1, 16], we consistently observed a protein spe-
cies of 35 KDa as the predominant species on immuno-
blots of urea-soluble lysates extracted from gray matter 
of the anterior horn of ALS lumbar spinal cord, with a 
25-kDa species observable after longer exposures. This 
may reflect differences in spinal cord versus brain tis-
sues, or perhaps the extent of degeneration in the regions 
sampled. In this regard, in all cases used for the current 
study, areas adjacent to the regions sampled for bio-
chemistry were confirmed to have remaining motor neu-
rons with TDP-43 pathology by immunohistochemical 
analysis. Indeed, subsequent to the original descriptions 
of lower molecular weight species of TDP-43 in disease 
tissues, several other groups have also reported the pres-
ence of 35-kDa species in both ALS and FTLD tissues 
[23, 30]. To determine if the pathologically associated 
TDP-43 species of 35 kDa observed in ALS spinal cord 
tissues was derived from alternate translation initiation or 
caspase-3 cleavage, we generated neo-epitope antibodies 
specific for the respective N-terminal sequences, start-
ing at Met85 or Asp90. The 35-kDa species observed on 
immunoblots of ALS tissues was detected using Met85-
TDP-35 antibody but not C3-TDP-35 antibody, indicating 
that in all the samples tested in this study (n = 12 ALS 
cases), this 35-kDa species is generated through an alter-
nate translation event starting at Met85. Analysis of urea-
soluble fractions from prefrontal cortex also revealed that 
a 35-kDa lower molecular weight species of TDP-43 was 
clearly present in four of six ALS-FTLD cases, absent 
in controls, and was also labeled with Met85-TDP-35 
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antibody, again suggesting that this pathological form of 
TDP-43 in the brain is generated by alternate translation 
starting at Met85.
Immunohistochemical analysis showed labeling of TDP-
43 pathology in motor neurons of ALS spinal cord with 
Met85-TDP-35 antibody, but not with C3-TDP-35 antibody. 
Fig. 6  Immunohistochemical 
characterization of Met85-
TDP-35 in ALS spinal cord. a 
Immunohistochemical analysis 
of serial sections from ALS and 
labeled with polyclonal TDP-43 
antibody (poly-TDP-43 Ab) and 
Met85-TDP-35 antibody (Met85-
TDP-35 Ab). Note that Met85-
TDP-35 immunoreactivity is 
localized to TDP-43-positive 
pathology (arrows). b Met85-
TDP-35 immunoreactivity was 
ablated by competition with the 
immunizing peptide (arrows). 
c There was no coincident 
labeling of TDP-43 pathol-
ogy with C3-TDP-35 antibody 
(C3-TDP-35 Ab). d Double 
immunofluorescence labeling of 
control and ALS spinal motor 
neurons with mouse monoclonal 
TDP-43 antibody (Mono TDP-
43; red) and Met85-TDP-35 
Ab (green), nuclei stained with 
DAPI (blue). Note labeling of 
motor neuron nucleus in control 
spinal cord with mono TDP-43 
antibody but not with Met85-
TDP-35 antibody (arrowhead), 
indicating lack of cross reactiv-
ity of Met85-TDP-35 Ab with 
full-length TDP-43. Conversely, 
Met85-TDP-35 immunoreactiv-
ity co-localized with TDP-43 
pathology in motor neurons of 
ALS cases (arrows). Asterisk 
indicates lipofuscin. Scale bars 
20 μm (a–c); 5 μm (d)
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Interestingly, Met85-TDP-35 antibody labeling was specific 
to TDP-43 pathology in motor neurons, suggesting that the 
event leading to expression of Met85-TDP-35 may be motor 
neuron specific. This could be important for understanding 
the selective vulnerability of motor neurons, and possibly 
other affected neuronal types in ALS-FTLD, especially as 
expression of Met85-TDP-35 can kill motor neurons. Future 
studies will be aimed at investigating this possibility. One 
of the normal functions of TDP-43 is in the regulation 
of alternative splicing and prior studies have shown that 
downregulation of TDP-43 can lead to changes in the splic-
ing profile of TDP-43 itself [2, 18]. As such, it is possible 
that the abnormalities of TDP-43 observed in ALS-FTLD 
could lead to expression of the TDP-43 r.[106_196del] 
transcript that generates Met85-TDP-35. Another possible 
mechanism is RNA perturbations caused by G4C2 hexa-
nucleotide repeat expansions in C9orf72, the most com-
mon known genetic cause of ALS-FTLD and typified by 
TDP-43 pathology [10, 19, 20]. RNA foci generated by 
the expansions are observed in disease-affected neurons, 
sequestering RNA-binding proteins from their normal tar-
gets, which could include TDP-43 and thereby lead to 
splicing irregularities and generation of Met85-TDP-35. 
In support of this, both the TDP-43 r.[106_196del] tran-
script and Met85-TDP-35 were found in the ALS cases with 
C9orf72 repeat expansions, as well as sALS cases.
Based on our observations in culture, expression of 
Met85-TDP-35 would lead to sequestering of full-length 
TDP-43 from the nucleus to form cytoplasmic aggregates 
and cause neuronal death, an idea that has been promul-
gated previously [26]. As such, understanding the mecha-
nism that generates Met85-TDP-35 could have therapeu-
tic potential. Finally, although we have shown that the 
splice variant TDP-43 r.[106_196del] can generate Met85-
TDP-35, there could be additional mechanisms that lead 
to use of ATGMet85 as an alternate translation start site and 
these remain to be explored.
In conclusion, we have identified a splice variant of 
TDP-43 that is upregulated in ALS and generates a protein 
species of 35 kDa through alternate translation initiation at 
ATGMet85, called Met85-TDP-35. A neo-epitope antibody 
specifically recognizing Met85-TDP-35 labeled the patho-
logically associated 35-kDa species on immunoblots of 
ALS-FTLD tissue extracts, and co-labeled TDP-43 pathol-
ogy. Presence of Met85-TDP-35 was specific to affected 
motor neurons and could provide a potential mechanism 
for TDP-43-mediated neurotoxicity in disease.
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